Cellino at Disrupt 2021 Startup Battlefield Finals

Cellino: Pioneering Personalized Cell Therapies

This information was documented on September 23, 2021. Cellino is dedicated to broadening access to autologous, personalized cell therapies for individuals in need.

The company anticipates that regenerative medicines derived from stem cells will offer cures for challenging diseases, such as Parkinson’s disease, diabetes, and heart disease, before the end of this decade.

The Advantage of Patient-Specific Cells

Utilizing cells specific to each patient is believed to provide the most secure and impactful therapeutic outcomes. This approach minimizes the risk of rejection and maximizes efficacy.

Cellino’s Innovative Platform

Cellino’s proprietary technology leverages AI-guided lasers to enable the large-scale production of personalized regenerative medicines. This represents a significant advancement in the field.

For the first time, it is possible to manufacture these tailored therapies efficiently and consistently, paving the way for wider patient availability.

The platform allows for the creation of regenerative medicines that are uniquely suited to each individual’s biological needs.